Jaguar health shares presentation replay link from september 11-13, 2023 h.c. wainwright annual global investment conference

Click here to access webcast replay top line results expected late october 2023 for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / september 14, 2023 / jaguar health, inc. (nasdaq:jagx), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (gi) prescription medicines, today announced that the recording of the company's virtual presentation at the september 11-13, 2023 h.c. wainwright 25th annual global investment conference can be accessed by clicking here.
JAGX Ratings Summary
JAGX Quant Ranking